Scarica l'app Stockscreener
2.04
1.92%
-0.04
Pre-mercato:
2.07
0.03
+1.47%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GDRX Giù?
Forum
Previsione
Precedente Chiudi:
$2.08
Aprire:
$2.08
Volume 24 ore:
1.67M
Relative Volume:
0.55
Capitalizzazione di mercato:
$698.85M
Reddito:
$796.85M
Utile/perdita netta:
$30.44M
Rapporto P/E:
24.23
EPS:
0.0842
Flusso di cassa netto:
$93.88M
1 W Prestazione:
-8.52%
1M Prestazione:
-13.92%
6M Prestazione:
-48.87%
1 anno Prestazione:
-56.03%
Intervallo 1D:
$2.0337
$2.095
Intervallo di 1 settimana:
$2.00
$2.22
Portata 52W:
$1.77
$5.8099
Goodrx Holdings Inc Stock (GDRX) Company Profile
Nome
Goodrx Holdings Inc
Settore
Industria
Telefono
(855) 268-2822
Indirizzo
2701 OLYMPIC BOULEVARD, SANTA MONICA
Compare GDRX vs VEEV, TEM, BTSG, HQY, WAY
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GDRX
Goodrx Holdings Inc
|
2.04 | 698.85M | 796.85M | 30.44M | 93.88M | 0.0842 |
VEEV
Veeva Systems Inc
|
179.11 | 29.44B | 3.20B | 908.91M | 1.39B | 5.4168 |
TEM
Tempus Ai Inc
|
48.83 | 8.73B | 1.27B | -245.03M | -245.36M | -1.4071 |
BTSG
Brightspring Health Services Inc
|
43.31 | 8.32B | 12.91B | 104.80M | 394.69M | 0.8769 |
HQY
Healthequity Inc
|
82.10 | 6.94B | 1.31B | 215.20M | 408.32M | 2.4627 |
WAY
Waystar Holding Corp
|
24.03 | 4.61B | 1.10B | 112.09M | 283.19M | 0.6096 |
Goodrx Holdings Inc Stock (GDRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-27 | Downgrade | JP Morgan | Overweight → Neutral |
| 2026-01-22 | Downgrade | Jefferies | Buy → Hold |
| 2025-12-09 | Iniziato | Barclays | Underweight |
| 2025-08-11 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2024-12-04 | Iniziato | Mizuho | Neutral |
| 2024-08-09 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-05-23 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-05-16 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2024-04-10 | Aggiornamento | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2024-03-25 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-03-01 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-02-26 | Iniziato | Leerink Partners | Outperform |
| 2024-01-02 | Downgrade | BofA Securities | Buy → Underperform |
| 2023-08-10 | Aggiornamento | DA Davidson | Neutral → Buy |
| 2023-07-31 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2022-12-01 | Iniziato | Citigroup | Buy |
| 2022-11-04 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2022-09-16 | Iniziato | KeyBanc Capital Markets | Sector Weight |
| 2022-09-07 | Iniziato | Truist | Hold |
| 2022-08-12 | Iniziato | DA Davidson | Neutral |
| 2022-06-10 | Downgrade | Goldman | Buy → Neutral |
| 2022-06-06 | Ripresa | BofA Securities | Buy |
| 2022-06-01 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2022-05-10 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-05-10 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-05-10 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2022-05-10 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-04-11 | Iniziato | Wells Fargo | Equal Weight |
| 2022-04-07 | Iniziato | Guggenheim | Buy |
| 2022-04-01 | Ripresa | Credit Suisse | Neutral |
| 2022-03-15 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2022-03-01 | Reiterato | Barclays | Overweight |
| 2022-03-01 | Reiterato | BofA Securities | Neutral |
| 2022-03-01 | Downgrade | Cowen | Outperform → Market Perform |
| 2022-03-01 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2022-03-01 | Reiterato | Evercore ISI | Outperform |
| 2022-03-01 | Reiterato | Goldman | Buy |
| 2022-03-01 | Reiterato | JP Morgan | Underweight |
| 2022-03-01 | Reiterato | RBC Capital Mkts | Outperform |
| 2022-03-01 | Reiterato | SVB Leerink | Outperform |
| 2022-01-07 | Iniziato | Goldman | Buy |
| 2021-12-21 | Iniziato | Stephens | Overweight |
| 2021-12-02 | Iniziato | Jefferies | Buy |
| 2021-08-31 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2021-08-13 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2021-05-28 | Iniziato | Robert W. Baird | Neutral |
| 2021-04-06 | Ripresa | Evercore ISI | Outperform |
| 2021-01-25 | Iniziato | Guggenheim | Buy |
| 2020-11-19 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-10-19 | Iniziato | Barclays | Equal Weight |
| 2020-10-19 | Iniziato | BofA Securities | Neutral |
| 2020-10-19 | Iniziato | Citigroup | Buy |
| 2020-10-19 | Iniziato | Cowen | Outperform |
| 2020-10-19 | Iniziato | Credit Suisse | Outperform |
| 2020-10-19 | Iniziato | Deutsche Bank | Hold |
| 2020-10-19 | Iniziato | Goldman | Neutral |
| 2020-10-19 | Iniziato | JP Morgan | Neutral |
| 2020-10-19 | Iniziato | Morgan Stanley | Overweight |
| 2020-10-19 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2020-10-19 | Iniziato | SVB Leerink | Outperform |
| 2020-10-19 | Iniziato | UBS | Buy |
Mostra tutto
Goodrx Holdings Inc Borsa (GDRX) Ultime notizie
How The Reset In Expectations Is Reframing The GoodRx Holdings (GDRX) Investment Story - Yahoo Finance
If You Invested $1,000 in Goodrx Holdings, Inc. (GDRX) - Stock Titan
Dow Update: Can GoodRx Holdings Inc expand its profit margins2026 Final Week & Weekly Hot Stock Watchlists - baoquankhu1.vn
GoodRx Holdings, Inc. Announces Dismissal of PwC as Independent Auditor in March 2026 - Minichart
GoodRx (GDRX) replaces PwC with KPMG as independent auditor for 2026 - Stock Titan
Morgan Stanley favors GoodRx (GDRX) and healthcare tech over managed care for 2026 citing strong market-beating potential - MSN
GoodRx stock ticks up after launching weight-loss subscription service - MSN
GoodRx Holdings, Inc. (NASDAQ:GDRX) Receives Average Rating of "Hold" from Brokerages - MarketBeat
Strategy Pivot Hits GoodRx - Los Angeles Business Journal
Lakewood Capital Management LP Decreases Position in GoodRx Holdings, Inc. $GDRX - MarketBeat
GoodRx (GDRX) director exercises 192K options and gifts 150K Class A shares - Stock Titan
GoodRx Holdings, Inc.Class A Common Stock (NQ: GDRX - The Chronicle-Journal
Published on: 2026-03-12 03:47:43 - baoquankhu1.vn
GoodRx (NASDAQ:GDRX) Shares Down 6%Time to Sell? - MarketBeat
GoodRx Holdings, Inc. announced that consumers paying with cash through its platform can enjoy up to 85% discounts on medications at more than 70,000 pharmacies across the United States. - Bitget
GoodRx (GDRX) Partners with Viatris for Major Medication Discoun - GuruFocus
GoodRx offers up to 85% discount on Viatris drugs (GDRX) - Seeking Alpha
GoodRx Partners with Viatris to Offer Up to 85% Savings on Established Brand Medications - ChartMill
GoodRx (GDRX) CAO converts RSUs to stock and withholds shares for taxes - Stock Titan
GoodRx: Losing Relevance With Consumers (Downgrade) (NASDAQ:GDRX) - Seeking Alpha
GoodRx (GDRX) Q4 2025 Earnings Call Transcript - AOL.com
Aug Technicals: How does GoodRx Holdings Inc perform in inflationary periods2025 Investor Takeaways & Verified Momentum Stock Ideas - baoquankhu1.vn
Aug Reactions: Is GoodRx Holdings Inc showing insider buyingMarket Movement Recap & Short-Term High Return Ideas - baoquankhu1.vn
GoodRx awards discretionary cash bonus to chief accounting officer - Investing.com UK
GoodRx awards discretionary cash bonus to chief accounting officer By Investing.com - Investing.com South Africa
GoodRx Awards Performance-Based Bonus to Chief Accounting Officer - TipRanks
GoodRx approves $72,918 discretionary bonus for Chief Accounting Officer Romin Nabiey - TradingView
GoodRx (GDRX) Board approves $72,918 bonus for Chief Accounting Officer - Stock Titan
U.S. medical discount service provider GoodRx Holdings, Inc. recently announced the launch of an innovative subsidy program for self-insured employers. - Bitget
GoodRx to expand employer-sponsored access to Zepbound® Kwikpen® - marketscreener.com
Obesity drug Zepbound now offered to workers at $449 through GoodRx - Stock Titan
[Form 4] GoodRx Holdings, Inc. Insider Trading Activity - Stock Titan
GoodRx (NASDAQ: GDRX) grants 1.33M RSUs to director Wendy Barnes - Stock Titan
GDRX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
GDRX: Wells Fargo Maintains Rating, Lowers Price Target by 50% | - GuruFocus
Wells Fargo & Company Has Lowered Expectations for GoodRx (NASDAQ:GDRX) Stock Price - MarketBeat
GoodRx Holdings (GDRX) Analyst Rating Update: Citigroup Lowers P - GuruFocus
Citigroup Lowers GoodRx (NASDAQ:GDRX) Price Target to $3.50 - MarketBeat
GoodRx Holdings, Inc. (GDRX) Stock Analysis: A 51.74% Upside Potential Awaits Investors - DirectorsTalk Interviews
GDRX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
GoodRx (NASDAQ:GDRX) Trading Up 9.4%Should You Buy? - MarketBeat
The Goldman Sachs Group Lowers GoodRx (NASDAQ:GDRX) Price Target to $2.50 - MarketBeat
Goldman Sachs Lowers GoodRx Holdings (GDRX) Price Target to $2.5 - GuruFocus
Goodrx Holdings Inc receives Investment Bank Analyst Rating Update By Investing.com - Investing.com
GoodRx Earnings Call Marks Transitional Reset Year - TipRanks
GoodRx Announces Resignation of Board Member Dipanjan Deb - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: GoodRx Holdings (GDRX) and Vericel (VCEL) - The Globe and Mail
Assessing GoodRx Holdings (GDRX) Valuation After Employer Direct Launch And Post Earnings Analyst Shifts - simplywall.st
Why GoodRx (GDRX) Is Down 19.4% After Unveiling Employer Direct And 2026 Revenue Guidance - Yahoo Finance
GoodRx (GDRX) board member Dipanjan Deb steps down without dispute - Stock Titan
GoodRx Holdings (GDRX) Analyst Rating and Price Target Update | - GuruFocus
Goodrx Holdings Inc Azioni (GDRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.50%
2.28%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):